Is the Options Market Predicting a Spike in MiMedx Group Stock?
Investors need to pay close attention to MDXG stock based on the movements in the options market lately.
MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MiMedx (MDXG) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.06 per share a year ago.
Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline
MiMedx (MDXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript
MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, MiMedx Group, Inc (MDXG) is looking like an interesting pick, as it just reached a key level of support. MDXG's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
MiMedx: Breakout Setup Into A Policy Overhaul
MiMedx Group is positioned for growth, with strong earnings, record Q3 revenue, and a rising contribution from its Surgical business. MDXG is proactively managing 2026 reimbursement policy risks by shifting product mix, accepting near-term price pressure, and leveraging its MiMedx Connect platform. Valuation analysis suggests MDXG is undervalued by ~20%, with feasible revenue growth and FCF margin assumptions supported by recent financial performance.
MiMedx Group, Inc. (MDXG) Q3 2025 Earnings Call Transcript
MiMedx Group, Inc. ( MDXG ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Matthew Notarianni - Head of Investor Relations Joseph Capper - CEO & Director Douglas Rice - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Carl Byrnes - Northland Capital Markets, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2025 Operating and Financial Results Conference Call.
MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.07 per share a year ago.
MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Douglas C. Rice - Chief Financial Officer Joseph H.
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.08 per share a year ago.
